Does Ozempic Cause Muscle Loss?

A common question in obesity medicine is whether Ozempic causing muscle loss is a real concern, or whether this is simply a misunderstanding of how weight loss works. The most evidence-based answer is that Ozempic, whose active ingredient is semaglutide, can be associated with some loss of lean mass during weight loss, but that does not mean it uniquely “destroys muscle.” In clinical studies, semaglutide-based weight loss has generally reduced fat mass much more than lean mass, while still showing that some lean tissue is commonly lost during the process. (PMC)

This distinction matters. In the STEP 1 body composition substudy, adults treated with semaglutide 2.4 mg had substantial reductions in body weight, total fat mass, and visceral fat mass. Lean mass also declined, but the proportion of lean mass relative to total body weight actually increased because fat mass fell to a greater extent. In other words, semaglutide was not simply stripping away muscle. It was mainly driving fat loss, with some accompanying lean mass loss, which is common in almost all successful weight-loss interventions. (PMC)

That is the key point often missed in online discussions about Ozempic causing muscle loss. Weight loss itself, whether achieved through diet alone, surgery, lifestyle intervention, or medication, almost always includes some loss of lean tissue. Reviews on weight loss and body composition have consistently shown that calorie restriction and body weight reduction can lead to decreases in both fat mass and lean mass. This is not unique to Ozempic or to semaglutide. It is part of the biology of weight reduction. (PMC)

A 2024 systematic review of semaglutide and lean mass reached a similarly balanced conclusion. Across trials, semaglutide was associated with notable weight loss primarily from fat mass, but lean mass reductions were also observed. Importantly, the amount of lean mass loss varied across studies, and the available evidence did not support a simplistic conclusion that semaglutide causes abnormal or disproportionate muscle wasting in every patient. (PubMed)

This is where context matters for any Weight Loss Clinic or Men’s Health Clinic discussing the issue. A patient with obesity who loses weight may improve metabolic health, blood pressure, waist circumference, and body fat percentage, even if some lean mass is lost along the way. At the same time, preserving muscle remains important because skeletal muscle affects strength, function, insulin sensitivity, resting energy expenditure, and long-term body composition. That is why the conversation should not be framed as “does weight loss matter?” versus “does muscle matter?” Both matter. (PMC)

The more clinically useful question is not whether lean mass can decrease, but how to reduce the amount of unnecessary muscle loss during treatment. Evidence across weight-loss research suggests that resistance training is one of the most effective ways to help maintain lean mass during calorie restriction. Meta-analyses and reviews have found that resistance-based exercise can improve body composition and help preserve lean tissue during weight loss. (PMC)

Protein intake also matters. Reviews on diet strategy during weight loss have shown that higher protein intake and protein supplementation can help preserve lean body mass during energy restriction. This does not mean protein fully prevents muscle loss, but it appears to reduce the extent of lean tissue decline when combined with a structured weight-loss approach. (PMC)

For that reason, when clinics discuss Ozempic causing muscle loss, the topic is better understood as a body composition issue rather than a medication scandal. Any effective weight loss can result in some lean mass loss. The difference is whether fat loss is the primary driver, whether muscle-preserving strategies are in place, and whether the patient is being followed in a way that looks beyond the scale. This is one reason body composition tracking has become increasingly relevant in both a Weight Loss Clinic and a Men’s Health Clinic setting. A simple scale cannot distinguish fat loss from lean mass loss, while body composition assessment may provide a more accurate picture of what is actually happening during treatment. (PMC)

There is also growing discussion in the literature around “high-quality weight loss,” meaning weight reduction that prioritizes fat loss while trying to preserve muscle, function, and physical performance. More recent reviews on GLP-1 receptor agonists, including semaglutide, have emphasized that these drugs should be viewed within a broader obesity-treatment framework rather than as stand-alone tools. That broader framework includes exercise, nutrition, and ongoing monitoring of physical function and body composition. (PMC)

So, does Ozempic cause muscle loss? The neutral, evidence-based answer is that semaglutide-associated weight loss can include some decline in lean mass, but this is not unique to Ozempic and does not mean the medication mainly causes muscle wasting. The available evidence suggests that most of the weight lost is fat mass, while some lean mass loss can occur alongside it. Resistance training and adequate protein intake appear to be two of the most important strategies for mitigating that loss, regardless of whether weight reduction is achieved with medication or without it. (PMC) In addition, doing Body Composition Testing allows one to assess their weight changes more accurately.

In that sense, the phrase Ozempic causing muscle loss is only partly true. A more accurate way to frame it is this: all meaningful weight loss can lead to some muscle loss, and semaglutide is no exception, but the dominant effect in clinical trials has been fat loss, not isolated muscle loss. (PMC)